0000000000336789

AUTHOR

Pierre Amarenco

showing 3 related works from this author

Carotid Atherosclerosis Evolution When Targeting a Low-Density Lipoprotein Cholesterol Concentration70 mg/dL After an Ischemic Stroke of Atherosclero…

2020

Background: The TST trial (Treat Stroke to Target) showed the benefit of targeting a low-density lipoprotein cholesterol (LDL-C) concentration of <70 mg/dL in terms of reducing the risk of major cardiovascular events in 2860 patients with ischemic stroke with atherosclerotic stenosis of cerebral vasculature. The impact on carotid atherosclerosis evolution is not known. Methods: TST-PLUS (Treat Stroke to Target–Plaque Ultrasound Study) included 201 patients assigned to an LDL-C concentration of <70 mg/dL and 212 patients assigned to a target of 100±10 mg/dL. To achieve these goals, investigators used the statin and dosage of their choice and added ezetimibe as needed. Ultrasonographer…

Carotid atherosclerosisCarotid Artery DiseasesMalemedicine.medical_specialtyLow density lipoprotein cholesterol030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicinePhysiology (medical)Internal medicineMedicineHumansStrokeLipoprotein cholesterolAgedIschemic StrokeUltrasonographyAged 80 and overbusiness.industryCholesterol LDLMiddle Agedmedicine.diseaseEzetimibeHydroxymethylglutaryl-CoA Reductase InhibitorsIntima-media thicknessIschemic strokeCardiologyFemalePrevention controlCardiology and Cardiovascular Medicinebusiness030217 neurology & neurosurgeryFollow-Up StudiesCirculation
researchProduct

Benefit of Targeting a LDL (Low-Density Lipoprotein) Cholesterol \textless70 mg/dL During 5 Years After Ischemic Stroke

2020

Background and Purpose— The TST trial (Treat Stroke to Target) evaluated the benefit of targeting a LDL (low-density lipoprotein) cholesterol of <70 mg/dL to reduce the risk of cardiovascular events in 2860 patients with ischemic stroke with atherosclerotic stenosis of cerebral vasculature or aortic arch plaque >4 mm, in a French and Korean population. The follow-up lasted a median of 5.3 years in French patients (similar to the median follow-up time in the SPARCL trial [Stroke Prevention by Aggressive Reduction in Cholesterol Level]) and 2.0 years in Korean patients. Exposure duration to statin is a well-known driver for cardiovascular risk reduction. We report here the TST results …

Malemedicine.medical_specialtyStatinTime Factorsmedicine.drug_class[SDV]Life Sciences [q-bio]Brain IschemiaLDLchemistry.chemical_compoundDrug Delivery SystemsEzetimibeInternal medicinemedicineClinical endpointHumansangiographyMyocardial infarctionStrokeAgedAdvanced and Specialized NursingCerebral infarctionCholesterolbusiness.industryAnticholesteremic Agentsinformed consentcholesterolCholesterol LDLMiddle Agedmedicine.diseaseEzetimibestroke[SDV] Life Sciences [q-bio]aortachemistryNumber needed to treatCardiologyFemaleNeurology (clinical)Cardiology and Cardiovascular Medicinebusinessmedicine.drug
researchProduct

Long-term follow-up study of endarterectomy versus angioplasty in patients with symptomatic severe carotid stenosis trial

2014

Background and Purpose— We aimed at comparing the long-term benefit–risk balance of carotid stenting versus endarterectomy for symptomatic carotid stenosis. Methods— Long-term follow-up study of patients included in Endarterectomy Versus Angioplasty in Patients With Symptomatic Severe Carotid Stenosis (EVA-3S), a randomized, controlled trial of carotid stenting versus endarterectomy in 527 patients with recently symptomatic severe carotid stenosis, conducted in 30 centers in France. The main end point was a composite of any ipsilateral stroke after randomization or any procedural stroke or death. Results— During a median follow-up of 7.1 years (interquartile range, 5.1–8.8 years; maximum 1…

MaleRiskmedicine.medical_specialtymedicine.medical_treatment[SDV]Life Sciences [q-bio]Endarterectomylaw.inventionRandomized controlled triallawInterquartile rangeAngioplastyInternal medicinemedicineHumansCarotid StenosisProspective Studiescardiovascular diseasesStrokeAgedEndarterectomyAdvanced and Specialized Nursingbusiness.industryAngioplastyHazard ratioMiddle Agedmedicine.disease3. Good healthSurgeryStenosisTreatment OutcomeCardiologyFemaleStentsFranceNeurology (clinical)Carotid stentingCardiology and Cardiovascular MedicinebusinessFollow-Up Studies
researchProduct